Details for Patent: 8,753,665

✉ Email this page to a colleague

Which drugs does patent 8,753,665 protect, and when does it expire?

Patent 8,753,665 protects POSIMIR and is included in one NDA.

This patent has fifty-four patent family members in twenty-nine countries.

Summary for Patent: 8,753,665

Patent landscape, scope, and claims:

Title:	Controlled delivery system
Abstract:	The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. Preferably the composition contains bupivacaine and a sugar ester such as saib.
Inventor(s):	Verity; A. Neil (Sunnyvale, CA)
Assignee:	Durect Corporation (Cupertino, CA)
Application Number:	11/663,125
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,753,665

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,753,665

PCT Information
PCT Filed	September 15, 2005	PCT Application Number:	PCT/US2005/032863
PCT Publication Date:	March 30, 2006	PCT Publication Number:	WO2006/033948

International Family Members for US Patent 8,753,665

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E537844	⤷ Subscribe
Australia	2005287175	⤷ Subscribe
Brazil	PI0515372	⤷ Subscribe
Canada	2581287	⤷ Subscribe
China	101035562	⤷ Subscribe
Cyprus	1112625	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.